From the desk of guest author Joseph E. Gaugler, PhD, Professor and Robert L. Kane Endowed Chair in Long-Term Care and Aging, School of Public Health
On June 7, 2021, the Food and Drug Administration (FDA) approved Aducanumab (Aduhelm), the first new drug for Alzheimer’s disease in almost 20 years. Aducanumab is a medication that may help slow the progression of early stage Alzheimer’s disease.
Many people living with dementia, families, and care professionals have questions regarding this news. We’ve compiled a set of frequently asked questions and some answers, to provide you with a better understanding of what to expect with the FDA approval of Aducanumab.
Read the Full Brief: Aducanumab FAQ
Learn more about Joseph E. Gaugler, PhD
About Dr. Gaugler: His research examines the sources and effectiveness of long-term care for persons with Alzheimer’s disease and other chronic conditions. An applied gerontologist, Dr. Gaugler’s interests include Alzheimer’s disease and long-term care, the longitudinal ramifications of family care for persons with dementia and other chronic conditions, and the effectiveness of community-based and psychosocial services for older adults with dementia and their caregiving families.